« Return to News | CROs/Service Providers

Phase Forward Founder Steps Down

Thursday, October 9, 2008 01:00 PM

Dr. Paul Bleicher, chairman and founder of Waltham, Mass.-based eClinical technology company Phase Forward, will step down from his day-to-day operational responsibilities at the end of October. Phase Forward president and CEO Robert Weiler will also assume Bleicher’s role as chairman of the company’s board of directors, of which Bleicher will remain a member.

Other personnel news from the clinical trials industry:

Oncology contract research organization (CRO) Medelis, based in Phoenix, Ariz., named Deirdre Tessman managing director of Medelis Europe, the company’s new European division. Formerly of Tessman Technology and ILEX Pharmaceuticals, Tessman has directed all phases of pharmaceutical development from research through drug approval and marketing with additional expertise in the startup and turnaround of pharmaceutical companies.

Wilmington, Mass.-based Charles River Laboratories appointed Christophe Berthoux to the newly created position of executive vice president, global sales and marketing, and chief commercial officer. The goal of Charles River’s new global sales and marketing organization is to enhance the company’s ability to provide customers with a centralized, integrated approach to their drug development programs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.